Current Prices from Lipella Pharmaceuticals Inc. - Common Stock

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	LIPO	USD	31.07.2025 16:12	0,70 USD	-0,009 USD -1,27 %

Performance

Day	Week	Month	3 Months	6 Months	1 Year	5 Years
-1,27 %	-2,64 %	-18,58 %	-72,59 %	-73,75 %	-90,17 %	-98,48 %

Company Profile for Lipella Pharmaceuticals Inc. - Common Stock Share

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Company Data

Name Lipella Pharmaceuticals Inc. - Common Stock

Company Lipella Pharmaceuticals Inc.

Symbol LIPO

Website https://www.lipella.com

Primary Exchange

NASDAQ

ISIN US53630L1008

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Dr. Jonathan Kaufman M.B.A., Ph.D.

Market Capitalization 14 Mio

Country United States of America

Currency USD

Employees 0,0 T

Address 7800 Susquehanna St., 15208 Pittsburgh

IPO Date 2022-12-19

Stock Splits

Date	Split
08.11.2024	1:8

Ticker Symbols

Name	Symbol
NASDAQ	LIPO

More Shares

Investors who hold Lipella Pharmaceuticals Inc. - Common Stock also have the following shares in their portfolio:

DEV.BK JAPAN 17/27 MTN Bond

GRANADA GOLD MINE Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog